Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Jan

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Genomic Classifier Tests May Influence Treatment Decisions in Prostate Cancer Despite Lack of Evidence for Long Term Outcomes

Effect of KRAS Mutation Status on Treatment Outcomes in Metastatic Pancreatic Adenocarcinoma

Talquetamab Plus Teclistamab in Relapsed or Refractory Multiple Myeloma

Telephone Based Therapy May Reduce Fatigue Interference With Functioning in Metastatic Breast Cancer Survivors

Imlunestrant Alone or With Abemaciclib An All-Oral Targeted Therapy for ER-Positive Advanced Breast Cancer